Abstract
Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ER BB2, best known as HER 2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER 2/Neu therapy also requires CD4+ T cells and CD40/ CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.
Original language | English (US) |
---|---|
Article number | e27296 |
Journal | OncoImmunology |
Volume | 3 |
Issue number | 1 |
DOIs | |
State | Published - 2014 |
Keywords
- Adaptive immunity
- Antibody
- CD4
- CD40
- CD40L
- CD8
- HER2
- Herceptin
- Immunotherapy
- Neu
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology